Platelet-Rich Plasma for Knee Osteoarthritis
Platelet-rich plasma (PRP) can be considered as a treatment option for mild-to-moderate knee osteoarthritis after failure of conservative measures, but the evidence shows inconsistent results and you should prioritize intra-articular corticosteroid injections first, which have stronger supporting evidence.
Evidence Quality and Guideline Recommendations
The 2022 AAOS Clinical Practice Guideline 1 acknowledges that PRP has some supporting evidence (two high-quality and one moderate-quality study) showing reduced pain and improved function in knee osteoarthritis. However, the guideline explicitly notes critical limitations:
- Evidence demonstrates inconsistency, with worse treatment response in patients with severe knee osteoarthritis
- Concerns exist regarding cost and safety profile
- The evidence base is substantially weaker than for corticosteroid injections (which have 19 high-quality and 6 moderate-quality studies supporting their use)
The Strongest Recent Evidence Against PRP
The most important study to consider is the 2021 RESTORE trial 2, a rigorous, double-blind, placebo-controlled randomized trial of 288 patients with Kellgren-Lawrence grade 2-3 knee osteoarthritis. This high-quality study found:
- No significant difference in pain reduction at 12 months: PRP reduced pain by 2.1 points vs. 1.8 points for placebo (difference -0.4 points, p=0.17)
- No significant difference in cartilage volume preservation: medial tibial cartilage volume decreased 1.4% with PRP vs. 1.2% with placebo (p=0.81)
- 29 of 31 secondary outcomes showed no significant benefit
This contradicts the guideline's limited positive evidence and represents the highest quality, most recent definitive trial.
Conflicting Evidence
More recent studies 3, 4, 5 suggest PRP may provide benefit, particularly with higher platelet concentrations and in less severe disease. However, these studies are either meta-analyses of heterogeneous trials or smaller individual studies that don't match the methodological rigor of the RESTORE trial 2.
Clinical Algorithm for Your Patient
For a patient with mild-to-moderate knee osteoarthritis who has failed weight control, physical therapy, activity modification, and NSAIDs:
First-line injectable therapy:
- Intra-articular corticosteroid injection 1
- Strongest evidence base (19 high-quality studies)
- Provides approximately 3 months of benefit
- Lower cost and established safety profile
Second-line consideration (if corticosteroid fails or wears off):
- PRP may be offered with appropriate patient counseling 1
- Inform patient that the highest quality evidence shows no benefit over placebo 2
- Best reserved for patients with mild-to-moderate disease (not severe/Kellgren-Lawrence grade 4)
- Avoid in patients with severe osteoarthritis where evidence shows worse outcomes 1
- Discuss out-of-pocket costs (typically not covered by insurance)
Critical Caveats
Disease severity matters: The AAOS guideline 1 specifically notes worse treatment response in severe knee osteoarthritis. Your patient with mild-to-moderate disease falls within the potentially responsive range, but expectations should be tempered by the RESTORE trial results 2.
Avoid hyaluronic acid: Despite common use, the AAOS guideline 1 recommends against routine use of hyaluronic acid based on 17 high-quality and 11 moderate-quality studies showing inconsistent benefit (number needed to treat = 17).
Consider timing for arthroplasty: If symptoms remain refractory after corticosteroid and potentially PRP, the patient should be evaluated for total knee arthroplasty candidacy rather than pursuing additional injections.
Safety Profile
PRP demonstrates a favorable safety profile with mild, transient adverse events 5. The primary concerns are cost and lack of proven efficacy rather than safety risks.